Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor
首创转化生长因子-β 受体 I 型抑制剂 galunisertib（LY2157299 一水合物）的临床前评估
期刊:Oncotarget
影响因子:
doi:10.18632/oncotarget.23795
Jonathan M Yingling, William T McMillen, Lei Yan, Huocong Huang, J Scott Sawyer, Jeremy Graff, David K Clawson, Karen S Britt, Bryan D Anderson, Douglas W Beight, Durisala Desaiah, Michael M Lahn, Karim A Benhadji, Maria J Lallena, Rikke B Holmgaard, Xiaohong Xu, Faming Zhang, Jason R Manro, Philip
